## CLEAN VERSION OF REWRITTEN OR ADDED CLAIMS PURSUANT TO 37 CFR § 1.21 (c)(1)(i)

Please amend the following claims.

## BEST AVAILABLE COPY



22. (Twice Amended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.



28.

(Twice Ahaended) A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in a an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.



(Amended) a composition for the treatment of a microbial infection comprising, a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.



PATENT Attorney Docket No. UM-03663

RECEIVE SEP 2-3 2002

## APPENDIX II CLEAN VERSION OF THE ENTIRE SET OF PENDING CLAIMS PURSUANT TO 37 CFR § 1.121 (c)(3) BEST AVAILABLE COPY A solution for the treatment of a microbial infection, said solution comprising a sterile

- A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is aerosolized for administration to a subject.
- 23. The solution of Claim 22, wherein said leukotriene is leukotriene B<sub>4</sub>.
- 24. The solution of Claim 22, wherein said leukotriene is a cysteinyl leukotriene.
- 25. The solution of Claim 24, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C<sub>4</sub>, leukotriene D<sub>4</sub>, and leukotriene E<sub>4</sub>.
- 27. The solution of Claim 22, wherein said microbial infection comprises *Klebsiella* pneumoniae infection.
- 28. A solution for the treatment of a microbial infection, said solution comprising a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is in a an intratracheal instillation device, said instillation device is selected from the group consisting of an endotracheal tube and a bronchoscope for intratracheal administration to a subject.
- 29. The solution of Claim 28, wherein said leukotriene is leukotriene B<sub>4</sub>.
- 30. The solution of Claim 28, wherein said leukotriene is a cysteinyl leukotriene.
- 31. The solution of Claim 28, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene C<sub>4</sub>, leukotriene D<sub>4</sub>, and leukotriene E<sub>4</sub>.

- 32. The solution of Claim 28, wherein said microbial infection comprises *Klebsiella*pneumoniae infection.

  BEST AVAILABLE COPY
- 33. A composition for the treatment of a microbial infection comprising, a sterile liquid vehicle, an antibiotic and a leukotriene dissolved in said sterile liquid vehicle, wherein said solution is contained within a nebulizer.
- 34. The composition of Claim 33, wherein said leukotriene is leukotriene B<sub>4</sub>.
- 35. The composition of Claim 33, wherein said leukotriene is cysteinyl leukotriene.
- 36. The composition of Claim 33, wherein said cysteinyl leukotriene is selected from the group consisting of leukotriene  $C_4$ , leukotriene  $D_4$  and leukotriene  $E_4$ .
- 37. The composition of Claim 33, wherein said microbial infection comprises *Klebsiella* pneumoniae infection.